Abliva AB (publ)
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic … Read more
Abliva AB (publ) (NEVPF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.221x
Based on the latest financial reports, Abliva AB (publ) (NEVPF) has a cash flow conversion efficiency ratio of -0.221x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.66 Million) by net assets ($61.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Abliva AB (publ) - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Abliva AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Abliva AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abliva AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SOC D'EXP VIOR
F:VL5
|
-0.011x |
|
Samart Telcoms Public Company Limited
BK:SAMTEL
|
0.208x |
|
Flekkefjord Sparebank
OL:FFSB
|
N/A |
|
Mundoro Capital Inc
OTCQB:MUNMF
|
0.111x |
|
MCF Energy Ltd.
OTCGREY:MCFNF
|
-0.034x |
|
Multi Ways Holdings Ltd
NYSE MKT:MWG
|
0.214x |
|
Pantaflix AG
XETRA:PAL
|
-1.616x |
|
READING INTL A DL-01
F:46B
|
N/A |
Annual Cash Flow Conversion Efficiency for Abliva AB (publ) (2007–2024)
The table below shows the annual cash flow conversion efficiency of Abliva AB (publ) from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $61.69 Million | $-102.84 Million | -1.667x | -1411.07% |
| 2023-12-31 | $70.72 Million | $-7.80 Million | -0.110x | +88.64% |
| 2022-12-31 | $164.29 Million | $-159.56 Million | -0.971x | +64.64% |
| 2021-12-31 | $41.53 Million | $-114.08 Million | -2.747x | -470.72% |
| 2020-12-31 | $140.36 Million | $-67.56 Million | -0.481x | +15.06% |
| 2019-12-31 | $127.80 Million | $-72.41 Million | -0.567x | +13.88% |
| 2018-12-31 | $97.01 Million | $-63.83 Million | -0.658x | -19.82% |
| 2017-12-31 | $105.85 Million | $-58.12 Million | -0.549x | -61.08% |
| 2016-12-31 | $168.30 Million | $-57.38 Million | -0.341x | +21.50% |
| 2015-12-31 | $154.78 Million | $-67.22 Million | -0.434x | -7.34% |
| 2014-12-31 | $107.84 Million | $-43.63 Million | -0.405x | -58.20% |
| 2013-12-31 | $74.64 Million | $-19.09 Million | -0.256x | -31.92% |
| 2012-12-31 | $63.04 Million | $-12.22 Million | -0.194x | +27.39% |
| 2011-12-31 | $32.17 Million | $-8.59 Million | -0.267x | -119.40% |
| 2010-12-31 | $41.18 Million | $-5.01 Million | -0.122x | -94.02% |
| 2009-12-31 | $10.17 Million | $-637.78K | -0.063x | +67.02% |
| 2008-12-31 | $11.70 Million | $-2.22 Million | -0.190x | +65.42% |
| 2007-12-31 | $1.81 Million | $-997.92K | -0.550x | -- |